Know Cancer

forgot password

A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC)

Phase 1/Phase 2
18 Years
Not Enrolling
Lung Cancer

Thank you

Trial Information

A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed NSCLC
which is stage IIIB with malignant pleural effusion or stage IV and have failed therapy
with at least a standard first line chemotherapy regimen, or be intolerant of standard

- Patients may have non-measurable disease, or measurable disease, defined as at least
one lesion that can be accurately measured in at least one dimension (longest
diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with
spiral CT scan).

- Patients with asymptomatic or treated brain metastases will be eligible if they last
received therapy (including steroids) > 4 weeks from study entry and are felt to have
a low likelihood of rapid deterioration from their brain metastases.

- Patients must have had at least 1 prior systemic therapy for NSCLC, or have shown
intolerance to chemotherapy. Patients may not have received prior therapy with
bexarotene, ZD1839, or erlotinib (Tarceva).

- At least 4 weeks must have elapsed from the time of major surgery and patients must
have recovered from the effects of any significant procedure.

- A three week interval must have elapsed from the last dose of chemotherapy (30 days
for investigational therapy), prior to beginning protocol therapy (6 weeks if
nitrosoureas or mitomycin C). Palliative radiotherapy to bony sites of disease is
allowed while on trial and up to time of enrollment provided patient has no
significant side effects from the radiotherapy.

- Age >= 18 years.

- Life expectancy > 2 months.

- ECOG performance status 0-2.

- Women of childbearing potential must have a negative pregnancy test (serum ß HCG with
a sensitivity of at least 50 mlU/L) within 7 days prior to initiation of treatment
and must have used 2 reliable forms of effective contraception used simultaneously or
have been sexually abstinent for at least 4 weeks prior to the negative pregnancy
test through entry in the study. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician

- Retinoid class agents are known teratogens.

- Female patients and male patients with female partners of childbearing potential must
agree to sexual abstinence or to practice 2 reliable forms of effective contraception
used simultaneously during the entire period of bexarotene capsule treatment and for
at least 1 month after treatment is discontinued. Male patients must agree to use
condoms if they have a female sexual partner who is, or may become, pregnant.

- Patients must have normal organ and marrow function as defined below:

- leukocytes >= 3,000/ul

- absolute neutrophil count >= 1,500/ul

- platelets >= 100,000/ul

- total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) <= 2.5 X institutional upper limit of normal

- creatinine within normal institutional limits OR calculated creatinine clearance
>= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional

- triglycerides and cholesterol levels which are within normal limits or
"normalized" with medication

- Patients may take the following agents, but with caution due to interactions with
P450 metabolism: dexamethasone, protease inhibitors, ketoconazole and other azole
antifungals, erythromycin and other macrolides antibiotics, grapefruit juice, other
retinoid class drugs, beta-carotene compounds, and agents which enhance insulin
secretion and sensitivity. They may not take phenytoin, carbamazepine, rifampicin,
barbiturates, or St. John's Wort while on study.

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:- Insulin dependent diabetes

- Thyroid disease

- Patients may not have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or
mitomycin C) prior to entering the study and must have recovered from adverse events
due to agents administered more than 4 weeks earlier. Palliative radiotherapy is
allowed to bony sites of disease.

- Patients may not be receiving any other investigational agents or have received any
within 30 days prior to day 1 of study.

- Patients with known symptomatic brain metastases are excluded from this clinical
trial because of their poor prognosis, those with treated, asymptomatic brain
metastases are eligible proved they have not required any therapy including steroids
for at least 4 weeks.

- Patients with a history of allergic reactions or sensitivity attributed to compounds
of similar chemical or biologic composition to bexarotene and ZD1839 are excluded.

- Patients with triglycerides or cholesterol levels which are not within normal limits
or "normalized" with medication will be excluded.

- Patients will be excluded for uncontrolled intercurrent illness including, but not
limited to, ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements.

- Patients with another active malignancy except for non-melanoma skin cancers are

- Pregnant or breastfeeding women are excluded.

- Patients with risk factors for pancreatitis are excluded such as a history of
pancreatitis, significant alcohol consumption or other factors which are deemed to
put them at high risk.

- Patients taking systemic vitamin A in doses exceeding 15,000 IU/day within 14 days
of study entry will be excluded.

- Patients who are unwilling to minimize exposure to ultraviolet light (sunlight) while
on bexarotene will be excluded.

- Patients MAY NOT TAKE GEMFIBROZIL while on study due to interactions with bexarotene

- Patients may not take phenytoin, carbamazepine, rifampicin, barbiturates, or St
John's Wort while on the study.

- Patients with any evidence of clinically active interstitial lung disease will be
excluded (patients with chronic stable radiographic changes who are asymptomatic need
not be excluded)

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate (RECIST CRITERIA), time to progression, toxicity

Outcome Time Frame:

Completed 9/2005

Safety Issue:


Principal Investigator

Charlotte D Jacobs

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University


United States: Food and Drug Administration

Study ID:




Start Date:

April 2004

Completion Date:

December 2005

Related Keywords:

  • Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Stanford University School of MedicineStanford, California  94305-5317